Tryptanthrin Nanoliposomal Lotion as a Corticosteroid-Free Strategy for Safe and Effective Treatment of Atopic Dermatitis
Source abstract
Abstract
Atopic dermatitis is a chronic inflammatory skin disease characterized by dry skin, itching, and recurrent eczematous lesions. Although current therapeutic strategies are effective, their use is often limited due to adverse effects. Therefore, the development of safer and more effective alternatives is required. Tryptanthrin is a yellow-gold alkaloid compound with anti-atopic and various pharmacological activities. However, its poor aqueous solubility results in low topical bioavailability. A tryptanthrin-loaded liposomal lotion was developed using a design of experiments approach to improve topical delivery. The optimized formulation showed enhanced physicochemical stability and moisturizing properties, as well as improved drug release compared to free tryptanthrin. In human keratinocyte cells, the liposomal lotion exhibited lower cytotoxicity than the free tryptanthrin and demonstrated higher skin residual. In the DNCB-induced atopic dermatitis mouse model, the tryptanthrin-loaded liposomal lotion produced therapeutic effects comparable to or greater than those of 1.0% hydrocortisone, without inducing adverse effects such as skin atrophy. Overall, the tryptanthrin-loaded liposomal lotion is presented as a promising and safe strategy for the topical treatment of atopic dermatitis.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Dermatology and Skin Diseases · Quinazolinone synthesis and applications · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Pharmacy, Chungnam National University, Daejeon 31434, Republic of Korea.
College of Korean Medicine, Woosuk University, Jeonju, Republic of Korea.
Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chosun University, Gwangju, Republic of Korea.
College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.
Funding
National Research Foundation of Korea
References (50)
Show source-provided references
1. 10.1016/j.anai.2020.12.02010.1016/j.anai.2020.12.020 ↗
2. 10.1016/j.abb.2013.11.01010.1016/j.abb.2013.11.010 ↗
3. Lee EB, Kim KW, Hong JY, Jee HM, Sohn MH, Kim KE. Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. Pediatr Allergy Immunol. 2010;21(2 Pt 2):e457–e460.
4. 10.1038/ni80510.1038/ni805 ↗
5. 10.1186/1744-8069-6-6310.1186/1744-8069-6-63 ↗
6. 10.1038/nature0266410.1038/nature02664 ↗
7. 10.1038/cr.2010.16810.1038/cr.2010.168 ↗
8. 10.4049/jimmunol.178.3.139610.4049/jimmunol.178.3.1396 ↗
9. 10.1111/j.1346-8138.2009.00706.x10.1111/j.1346-8138.2009.00706.x ↗
10. 10.1016/j.jaad.2017.12.02210.1016/j.jaad.2017.12.022 ↗
11. 10.5414/ALX02272E10.5414/ALX02272E ↗
12. 10.1016/j.jaad.2005.04.05910.1016/j.jaad.2005.04.059 ↗
13. 10.1111/j.1365-2133.2010.10030.x10.1111/j.1365-2133.2010.10030.x ↗
14. Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis—A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology Guidelines. Alergol Pol. 2017;4(4):158–166.
15. 10.1111/j.1365-2133.2008.08813.x10.1111/j.1365-2133.2008.08813.x ↗
16. 10.1080/17512433.2018.144964210.1080/17512433.2018.1449642 ↗
17. 10.1016/j.bmc.2017.07.00310.1016/j.bmc.2017.07.003 ↗
18. Xin H, Qian Z, You-bei Q, Zhe Y, Hong W. Preparation and characterization of micellar tryptanthrin. Prog Mod Biomed. 2021;21(4).
19. 10.3390/molecules2615442910.3390/molecules26154429 ↗
20. 10.4103/2230-973X.11489910.4103/2230-973X.114899 ↗
21. 10.1016/j.ijpharm.2019.11891810.1016/j.ijpharm.2019.118918 ↗
22. 10.1016/j.jconrel.2016.09.00810.1016/j.jconrel.2016.09.008 ↗
23. 10.1186/s12951-024-02860-310.1186/s12951-024-02860-3 ↗
24. 10.1023/A:102018650584810.1023/A:1020186505848 ↗
25. Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297–315.
26. 10.1016/j.ejpb.2012.04.00510.1016/j.ejpb.2012.04.005 ↗
27. 10.1016/j.plipres.2012.10.00310.1016/j.plipres.2012.10.003 ↗
28. 10.1039/D1LC00812A10.1039/D1LC00812A ↗
29. 10.3389/fbioe.2021.70588610.3389/fbioe.2021.705886 ↗
30. 10.2147/IJN.S11928610.2147/IJN.S119286 ↗
31. Rodriguez C, Camino A, Taly A, Peñ E, Inatti A, Serrano X. Betamethasone dipropionate loaded in nanoliposomes vs conventional betamethasone dipropionate: Comparative study of permeability and penetrability in vitro and ex vivo. J Biosci Med. 2024;12(10):140–156.
32. Schneider A, Hommel G, Blettner M. Linear regression analysis: Part 14 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2010;107(44):776–782.
33. 10.1093/ilar.43.4.24410.1093/ilar.43.4.244 ↗
34. 10.1186/cc240110.1186/cc2401 ↗
35. 10.11606/issn.2237-4485.lev.2011.13228210.11606/issn.2237-4485.lev.2011.132282 ↗
36. 10.1007/s13346-022-01205-710.1007/s13346-022-01205-7 ↗
37. 10.4103/0250-474X.11982010.4103/0250-474X.119820 ↗
38. 10.3390/pharmaceutics1206049110.3390/pharmaceutics12060491 ↗
39. 10.3390/gels1104024510.3390/gels11040245 ↗
40. 10.1111/j.1600-065X.2011.01027.x10.1111/j.1600-065X.2011.01027.x ↗
41. 10.1016/S1081-1206(10)61095-210.1016/S1081-1206(10)61095-2 ↗
42. 10.1111/jdv.2025810.1111/jdv.20258 ↗
43. 10.1007/s10753-023-01943-x10.1007/s10753-023-01943-x ↗
44. 10.1016/j.intimp.2023.11090010.1016/j.intimp.2023.110900 ↗
45. 10.1046/j.1365-2036.1996.22164025.x10.1046/j.1365-2036.1996.22164025.x ↗
46. 10.1038/s41598-018-30404-x10.1038/s41598-018-30404-x ↗
47. 10.2147/CCID.S22421110.2147/CCID.S224211 ↗
48. Hwang-Bo J, Veerappan K, Moon H, Lee T-H, Lee K-W, Park J, Chung H. Parnassin, a novel therapeutic peptide, alleviates skin lesions in a DNCB-induced atopic dermatitis mouse model. Biomedicine. 2023;11(5):1389.
49. 10.1083/jcb.106.3.76110.1083/jcb.106.3.761 ↗
50. 10.1038/s41598-024-54797-010.1038/s41598-024-54797-0 ↗